Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Horm Metab Res ; 40(9): 607-13, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18792871

RESUMO

The aim of the study is to determine if attenuation of postprandial hyperglycemia, by acutely and chronically enhancing postprandial insulin secretion in insulin-resistant individuals, improves the endothelial dysfunction. We assessed postoral glucose-load endothelial function in 56 insulin-resistant subjects with the Flow-Mediated-Dilation (FMD) technique. We randomized subjects to intervention/control group, and examined the acute and chronic effect of nateglinide, an oral antidiabetic drug of rapid action. In the intervention group, postoral glucose-load (post-OGL) FMD delta values deteriorated when compared to pre-OGL values, most significantly at 3 h post-OGL, on the following days: on the first study day termed "Baseline day" (p=0.04); on both days after 3 months of nateglinide treatment [with nateglinide administered on study-day "acute+chronic" (p=0.01); and without nateglinide on study-day "Closing day", p=0.001]. Post-OGL changes in the control group were nonsignificant both at Baseline and on Closing day. After a single dose of nateglinide "Acute day", post-OGL FMD deterioration was abolished. There was an increment in post-OGL FMD delta values most significant at 2 h post-OGL (p=0.02). Insulin concentrations increased while glucose concentrations decreased on study-days with nateglinide when compared to study-days without (p=<0.001 for both insulin and glucose). Comparisons for insulin and glucose concentrations between days with nateglinide, and likewise between days without, showed no significant difference. Postglucose load endothelial dysfunction can be prevented by administration of nateglinide, however, after 3 months of nateglinide treatment, this effect is abolished. Chronically increased insulin secretion could counteract the initial beneficial effect of reduced glucose excursions. We found no relationship between postprandial hyperglycemia and post-OGL FMD.


Assuntos
Glicemia/metabolismo , Cicloexanos/uso terapêutico , Endotélio/fisiopatologia , Hiperglicemia/tratamento farmacológico , Hiperglicemia/fisiopatologia , Resistência à Insulina , Insulina/metabolismo , Fenilalanina/análogos & derivados , Estudos de Casos e Controles , Cicloexanos/farmacologia , Endotélio/efeitos dos fármacos , Feminino , Glucose/metabolismo , Humanos , Secreção de Insulina , Masculino , Pessoa de Meia-Idade , Nateglinida , Fenilalanina/farmacologia , Fenilalanina/uso terapêutico , Período Pós-Prandial/efeitos dos fármacos , Fatores de Risco , Vasodilatação/efeitos dos fármacos
2.
Exp Diabetes Res ; 2008: 672021, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18350125

RESUMO

BACKGROUND/AIMS: Postprandial hyperglycemia, an independent risk factor for cardiovascular disease, is accompanied by endothelial dysfunction. We studied the effect of oral glucose load on insulin and glucose fluctuations, and on postprandial endothelial function in healthy individuals in order to better understand and cope with the postprandial state in insulin resistant individuals. METHODS: We assessed post-oral glucose load endothelial function (flow mediated dilation), plasma insulin, and blood glucose in 9 healthy subjects. RESULTS: The largest increases in delta FMD values (fasting FMD value subtracted from postprandial FMD value) occurred at 3 hours after both glucose or placebo load, respectively: 4.80 +/- 1.41 (P = .009) and 2.34 +/- 1.47 (P = .15). Glucose and insulin concentrations achieved maximum peaks at one hour post-glucose load. CONCLUSION: Oral glucose load does not induce endothelial dysfunction in healthy individuals with mean insulin and glucose values of 5.6 mmol/L and 27.2 mmol/L, respectively, 2 hours after glucose load.


Assuntos
Glicemia/metabolismo , Endotélio Vascular/fisiologia , Glucose/farmacologia , Insulina/metabolismo , Glicemia/efeitos dos fármacos , Pressão Sanguínea , Eletrocardiografia , Endotélio Vascular/efeitos dos fármacos , Teste de Tolerância a Glucose , Humanos , Insulina/sangue , Secreção de Insulina , Cinética , Placebos , Valores de Referência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...